Project Grant W81XWH2210732

This federal Cooperative Agreement award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $310,185 to New York University School of Medicine to conduct analytical and clinical validation of a methylation-based assay to predict recurrence in patients with stage II melanoma. The project aims to refine and validate a 13-probe signature identified in previous research that can accurately identify melanoma recurrence and...

This Project Grant from the Department of the Army Medical Command, totaling $530,887, supports research from September 1, 2022 to August 31, 2025 aimed at developing a multimodal precision liquid biopsy to predict risk of melanoma recurrence. Funded under the Military Medical Research and Development program (CFDA 12.420), the award supports Macquarie University in Australia to investigate medical solutions for the battlefield and transform military and public health through innovative...

The National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded a $396,161 Project Grant to Olmeda Biosciences LLC, a small disadvantaged business located in San Diego, CA. The grant aims to develop a novel multiplex assay that uses aqueous humor (the clear fluid in the front chamber of the eye) to accurately predict the risk of metastasis in patients with uveal melanoma, a prevalent form of intraocular cancer. The project seeks to...

This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $203,610 to the University of Texas at Austin to develop a "laser microbiopsy" technique for minimally-invasive sampling of melanoma tissue. The key products and services to be delivered under this 3-year award (8/8/2024 - 7/31/2027) are: Refining and characterizing the performance of the laser microbiopsy hardware to enable pain-free, minimally-invasive tissue...

This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Precision Epigenomics Inc., a University of Arizona spin-out company, aims to conduct a multi-site clinical validation study to establish the Sentinel-MPE liquid biopsy assay as a new commercial molecular test for the diagnosis of malignant pleural effusions (MPEs). The $2,078,214 award supports two key objectives: 1) Establishing the diagnostic value of the Sentinel-MPE assay...

This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $679,188 to The Regents of the University of California, San Francisco to develop liquid biopsy tools for detecting and profiling malignant effusions associated with metastatic breast cancer. The key objectives are to: 1) Validate an AI-assisted, morphology-based platform to isolate circulating tumor cells from malignant effusions; 2) Perform molecular characterization...

This Project Grant award from the Department of the Army Medical Command provides $180,094 to Edith Cowan University in Australia under the Military Medical Research and Development program (CFDA 12.420). The grant funds research to develop a multimodal precision liquid biopsy to predict the risk of melanoma recurrence. The liquid biopsy approach aims to analyze blood samples for molecular markers that may indicate the likelihood of melanoma returning after initial treatment. By supporting...

This National Cancer Institute Project Grant under CFDA 93.394 "Cancer Detection and Diagnosis Research" will develop and validate a multi-stage, multi-modal biomarker to predict the risk of progression from oral premalignant lesions (OPLs) to oral cavity squamous cell carcinoma (OSCC). The project, titled "PROSPECT: Premalignant Oral Lesions Pathology and Epigenetic Risk Prediction Tool," will use a combination of cytology, histology, and epigenomics to create a risk...

The National Cancer Institute (NCI) awarded a $700,611 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to the Sloan-Kettering Institute for Cancer Research, a prominent non-profit cancer research organization in New York. The grant, titled "Practical Randomized Controlled Trial of Artificial Intelligence for Melanoma Diagnosis (PRACTA-MEL)", aims to determine the potential benefits and barriers to clinical adoption of AI technology for improving...

This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $419,133 to Massachusetts Institute of Technology (MIT) to develop the "AscitesPredict" technology. This zero-passage "ex vivo tumor biosensor" uses single-cell analysis and machine learning to evaluate cell identities and therapeutic sensitivities in patient ascites samples, which are often discarded in standard clinical...